In a report published Monday, RBC Capital Markets analyst Adnan Butt upgraded the rating on AVEO Pharmaceuticals, Inc. AVEO from Underperform to Sector Perform, and raised the price target from $2.00 to $3.00.
In the report, RBC Capital Markets noted, "Since the setback with tivozanib in renal cancer, AVEO has made progress on four fronts: 1) Restructuring, to extend cash into 2016, 2) Showing an ability to partner, (the unique OPHT deal), 3) Outlining a biomarker strategy (tivozanib in CRC), and 4) Finding a path for tivozanib in the EU. All routes may need partnerships but partnering also seems more possible now."
AVEO Pharmaceuticals closed on Friday at $1.50.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in